Adragos Pharma Completes Sanofi Site Acquisition in France

Adragos Pharma, a global contract development and manufacturing organization (CDMO), announced that it completed the acquisition of a commercial-scale sterile fill-finish facility in Maisons-Alfort, France, from Sanofi. The Maisons-Alfort site is one of Europe’s largest manufacturing facilities for sterile injectables, with industrial-scale capacity for pre-filled syringes (PFS), as well as liquid and lyophilized vials. 

The Maisons-Alfort site employees are joining Adragos Pharma, bringing with them expertise in Sterile Manufacturing, ensuring full operational continuity while preserving the technical excellence built over the years. This complete talent integration represents a major strategic asset for the site’s future.

This site significantly expands Adragos’ sterile injectables network, adding high-volume pre-filled syringe manufacturing capabilities to its existing vial and ampoule filling operations in Jura, Switzerland, and Livron, France. The combined platform establishes Adragos as one of the leading sterile injectables CDMOs in Europe.  

Dr. Andreas Raabe, Founder and CEO of Adragos Pharma, commented: 

“Maisons-Alfort is a landmark acquisition for Adragos and a defining step in our growth journey. We are adding one of Europe’s leading sterile manufacturing sites to our network. Our ambition is clear: to invest, scale, and further develop the site into a top-tier fill-finish platform. This transaction is fully aligned with our strategy to secure and expand highly differentiated pharmaceutical manufacturing capacity in Europe.”